• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biotricity Launches Instant At-Home Heart Health Screening Service, HeartSecure

    6/28/24 7:35:30 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email

    Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announced its groundbreaking direct-to-consumer heart health screening service, HeartSecure, is now available for purchase online at HeartSecure.

    Heart disease remains the leading cause of death worldwide, with someone succumbing to cardiovascular disease (CVD) every 1.5 seconds. In the United States alone, 127 million adults have at least one risk factor for heart disease, contributing to one out of every three deaths. Traditional pathways for cardiac screening can involve wait times of up to two months for an appointment and even longer for test results. HeartSecure addresses these delays by providing immediate, at-home results, significantly improving accessibility and timeliness in cardiac care.

    Key Benefits of HeartSecure:

    Immediate Results: Patients can now receive cardiac screening results instantly, right from the comfort of their own homes.

    Accessibility: No more long waits for appointments and results-HeartSecure offers a seamless solution to proactive heart health management.

    Affordability: HeartSecure is an affordable option for comprehensive cardiac monitoring.

    "At Biotricity, we are committed to leveraging disruptive innovation to enhance lives," says Dr. Waqaas Al-Siddiq, Founder and CEO at Biotricity. " HeartSecure exemplifies our mission by transforming the industry, creating new revenue streams, and delivering significant value to our shareholders. More importantly, it democratizes access to critical cardiac screenings, ultimately saving and improving lives."

    HeartSecure stands as a monumental leap in cardiac monitoring, providing unparalleled convenience and peace of mind. By empowering individuals to take control of their cardiac health, Biotricity is reshaping the landscape of heart care. Learn more and purchase HeartSecure online today at HeartSecure.

    The home healthcare market, a rapidly growing sector, was valued at approximately $250 billion in 2023 and is expected to grow at an 8.9% CAGR, reaching $383 billion by 2028, according to a recent MarketsandMarkets report. This growth underscores the increasing demand for accessible and convenient healthcare solutions like HeartSecure.

    Get the next $BTCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

    REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

    11/14/25 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    SEC Filings

    View All

    Biotricity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIOTRICITY INC. (0001630113) (Filer)

    2/18/26 5:30:35 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Biotricity Inc.

    10-Q - BIOTRICITY INC. (0001630113) (Filer)

    2/11/26 4:29:05 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form S-1 filed by Biotricity Inc.

    S-1 - BIOTRICITY INC. (0001630113) (Filer)

    12/22/25 5:29:37 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biotricity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Biotricity from Buy to Neutral

    11/20/23 7:21:43 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Biotricity with a new price target

    Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

    3/7/22 9:01:18 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Biotricity with a new price target

    HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

    11/23/21 6:29:32 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosa David A

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/15/23 4:22:52 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Al-Siddiq Waqaas

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/14/23 4:26:54 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Ayanoglou John

    4 - BIOTRICITY INC. (0001630113) (Issuer)

    3/13/23 4:10:59 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

    REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

    11/14/25 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biotricity Inc.

    SC 13G - BIOTRICITY INC. (0001630113) (Subject)

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care